# A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

> **NCT06186492** · PHASE1 · COMPLETED · sponsor: **Wave Life Sciences Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Alpha-1 Antitrypsin Deficiency (AATD)

## Interventions

- **DRUG:** WVE-006

## Key facts

- **NCT ID:** NCT06186492
- **Lead sponsor:** Wave Life Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-14
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186492, "A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06186492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*